Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Clinical response will be assessed by the percentage of patients achieving a reduction from Baseline in Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) \[DAS28(ESR)\] score of greater than 1.2 points, which is considered the minimum clinically important difference.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent is signed and dated
The patient is considered capable of and prepared to adhere to the study protocol procedures
The patient is prescribed CZP according to the Summary of Product Characteristics (SmPC) (UK and Eire) and National Institute of Clinical Excellence (NICE) (UK only) guidelines for anti tumor necrosis factor (TNF) α therapy for Rheumatoid Arthritis (RA).
The patient is screen-negative for tuberculosis
The patient is 18 years of age or above
You may not be if
The patient has been exposed previously to biological disease modifying anti rheumatic drugs (DMARD) agents.
Patient has previously participated in this study or the patient has previously been assigned to treatment in a study of CZP or another biological agent used to treat RA.
Patient has participated in another study within the last 30 days
Patient has any medical or psychiatric condition that, in the opinion of the physician, can jeopardize or would compromise the patient's ability to adequately participate in the study
Patient has inadequate literacy to understand and complete the questionnaires.
